Literature DB >> 8313372

Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).

L M Ching1, W R Joseph, K E Crosier, B C Baguley.   

Abstract

The investigational antitumor agent, 5,6-dimethylxanthenone-4-acetic acid (5,6-MeXAA; NSC 640488) induced greater expression of tumor necrosis factor-alpha (TNF-alpha) mRNA in murine spleen cells in vivo at its optimal dose of 27.5 mg/kg than flavone acetic acid (FAA; NSC 347512) at its optimal dose of 220 mg/kg. Up-regulation of TNF-alpha mRNA was obtained using 5,6-MeXAA in vitro in cultures of murine splenocytes, the murine J774 macrophage cell line, and the human HL-60 myelomonocytic leukemia cell line. Maximal induction occurred at a 5,6-MeXAA concentration of 200 micrograms/ml for both murine J774 and human HL-60 cells. A direct comparison of FAA and 5,6-MeXAA (100-600 micrograms/ml) to stimulate TNF-alpha mRNA in HL-60 cells showed activity by 5,6-MeXAA at all doses but minimal activity with FAA. The results demonstrate that 5,6-MeXAA is equally potent in up-regulating TNF-alpha mRNA in human and murine cells of the monocyte/macrophage lineage, whereas FAA has demonstrable activity in murine cells only. The results suggest that 5,6-MeXAA would be a more active clinical agent than FAA because TNF-alpha induction appears to be a critical factor in the antitumor effects of this class of compounds.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8313372

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  Vascular targeting agents.

Authors:  Mary Jo Pilat; Julie McCormick; Patricia Mucci LoRusso
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA.

Authors:  M E Watts; S Arnold; D J Chaplin
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 3.  Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Authors:  Bruce C Baguley; Dietmar W Siemann
Journal:  Expert Opin Investig Drugs       Date:  2010-11       Impact factor: 6.206

Review 4.  5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.

Authors:  Shufeng Zhou; Philip Kestell; Bruce C Baguley; James W Paxton
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

5.  Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  M Philpott; B C Baguley; L M Ching
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.

Authors:  L M Ching; W R Joseph; L Zhuang; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).

Authors:  M Philpott; W R Joseph; K E Crosier; B C Baguley; L M Ching
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.

Authors:  G J S Rustin; C Bradley; S Galbraith; M Stratford; P Loadman; S Waller; K Bellenger; L Gumbrell; L Folkes; G Halbert
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

9.  Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Authors:  M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.

Authors:  K Hori; S Saito; K Kubota
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.